Cadence Bank에 대한 매도 수량은 투자자에게 Cadence Bank의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Cadence Bank (NYSE:CADE) 주식, 공매도 수량 보고

CADENCE BANK

Cadence Bank

Cadence Bank is a bank based in the United States. The operating segments are Corporate Banking segment focuses on C&I, business banking, and commercial real estate lending to clients in the geographic footprint, Community Banking segment provides a broad range of banking services through the branch network to serve the needs of community businesses and individual consumers in the geographic footprint, Mortgage segment includes mortgage banking activities of originating mortgage loans, selling mortgage loans in the secondary market and servicing the mortgage loans, Banking Services segment offers individuals, businesses, governmental institutions, and non-profit entities a widerange of solutions to help protect, grow, and transfer wealth, General Corporate and Other segment.

Cadeler AS

Cadeler A/S American Depositary Share (each representing four (4) Ordinary Shares)

Cadence Design Systems, Inc. - Common Stock

Cadence Design Systems Inc

CANDENCE MINERALS PLC NEW by Cadence Minerals plc

Cadence Minerals PLC

<a href="https://img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/85eced54-836a-40c0-8930-1cd103c8229c/Culper_APP_6-12-2025.pdf?ver=1749740950549" title="https://img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/85eced54-836a-40c0-8930-1cd103c8229c/Culper_APP_6-12-2025.pdf?ver=1749740950549">https://img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/85eced54-836a-40c0-8930-1cd103c8229c/Culper_APP_6-12-2025.pdf?ver=1749740950549</a>

News

Short Sellers

Trading Ideas

Watching Applovin; Culper Research Issues Report, Stating They Are Short On The Co

Houston American Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) shares are soaring over 27% in Thursday trading, becoming a top trending stock on social media platforms.
The significant upward movement is possible linked to <a href="https://www.benzinga.com/news/topics/25/06/45893521/us-embassy-evacuations-spark-middle-east-risks-and-markets-are-noticing">escalating</a> geopolitical tensions in the Middle East, which are driving a rally in crude oil prices and fueling speculative interest in energy-related equities.
What To Know: The move in the energy sector follows reports that the U.S. is withdrawing nonessential staff from several embassies in the Middle East. This development, <a href="https://www.benzinga.com/news/topics/25/06/45893521/us-embassy-evacuations-spark-middle-east-risks-and-markets-are-noticing">combined</a> with heightened nuclear tensions between Washington and Tehran, has stoked market fears of a potential conflict, pushing oil prices sharply higher. 
As an oil and gas exploration and production company, Houston American Energy benefits directly from the spike in energy commodity prices. By mid-morning, the stock&#8217;s trading volume had already soared past 650,000 shares, dwarfing its 100-day average of roughly 47,000 shares and signaling intense investor momentum.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, HUSA gapped up at the market open and traded as high as $6.90 during the session. The aggressive price action is also potentially amplified by a high level of short interest. 
Benzinga Pro data also indicates that 28.23% of the company&#8217;s float is sold short. This can create a &#8220;short squeeze&#8221; as short sellers are forced to buy shares to cover their positions, further accelerating the stock&#8217;s ascent.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45905997/gamestop-stock-is-facing-selling-pressure-thursday-whats-going-on">GameStop Stock Is Facing Selling Pressure Thursday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy HUSA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Houston American Energy&#8217;s case, it is in the Energy sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from Benzinga Pro, HUSA has a 52-week high of $32.00 and a 52-week low of $3.85.
Image: Shutterstock

HUSA

Houston American Energy (HUSA) Stock Soars Over 27%: What's Going On?

<a href="https://www.theinformation.com/articles/financial-markets-giant-dtcc-explores-stablecoin">https://www.theinformation.com/articles/financial-markets-giant-dtcc-explores-stablecoin</a>

General

$USDT

CRCL

'Financial Markets Giant DTCC Explores a Stablecoin'- The Information

Papa John's International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) shares are<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> trading lower on Thursday.</a>
On Wednesday, several media reports emerged that the company may be nearing a significant ownership change, as private equity giant Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) and Qatari-backed investment firm Irth Capital have reportedly joined forces to pursue a buyout of the pizza chain, valuing it at approximately $2 billion.
Semafor <a href="https://www.semafor.com/article/06/11/2025/papa-johns-pzza-apollo-take-private" target="_blank" rel="noreferrer noopener">reports </a>that the offer is in the low $60s per share, notably higher than the current stock price of around $48, citing sources familiar with the situation.
While Apollo has a history of large-scale acquisitions, Irth Capital is a much smaller player with less than $200 million in assets as of late 2023. Irth, backed by Sheikh Mohamed al Thani of Qatar's royal family, holds a 5% stake in Papa John's.
Following the reports, PZZA stock surged over 7% on Wednesday.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45629288/pizza-stocks-in-focus-analyst-says-dominos-gains-share-papa-johns-holds-steady-pizza-hut-loses-ground" rel="noreferrer noopener">Pizza Power Play: Analyst Says Domino&#8217;s Gains Share, Papa Johns Holds Steady, Pizza Hut Loses Ground</a>
Despite its size, Irth has experience with consumer-focused turnarounds, having been involved in the acquisitions of Casper and Bojangles.
Irth reportedly still needs to secure financing for its portion of the proposed deal, Semafor adds.
If that doesn't materialize, Apollo could move forward on its own.
As of now, neither Apollo nor Papa John's have issued public statements, and Irth has not responded to requests for comment.
If a formal sales process is launched, more potential suitors could emerge. Inspire Brands, known for its acquisition of Dunkin' Donuts in 2020, may explore the opportunity, Semafor further adds.
Another possibility is Roark Capital, which recently completed a deal for Dave's Hot Chicken and owns Subway.
Papa John's franchising model, which licenses branding and ingredients to independent operators, aligns with their typical investment strategies, the report further states.
In 2018 and 2019, Papa John's faced a public controversy involving its founder, John Schnatter, who used a racial slur during a conference call, Reuters reports. The incident led to legal disputes and, ultimately, a deal with activist investor Starboard Value, whose CEO took over as chairman of the board in 2019 following Schnatter's departure.
Although Starboard helped stabilize Papa John's, industry observers believe more changes are needed—fueling speculation of a potential take-private move to enable deeper restructuring out of public view, Reuters adds.
Under current CEO Todd Penegor, Papa John's has made notable performance improvements, though its stock continues to trade at a slight discount compared to peers like Yum! Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) and Domino's Pizza Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>).
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45902987/producer-inflation-rises-less-than-forecasts-in-may-jobless-claims-signal-labor-market-cracks" target="_blank" rel="noreferrer noopener">Producer Inflation Rises Less Than Forecasts In May, Jobless Claims Signal Labor Market Cracks</a></li>
</ul>
Photo: Shutterstock

Equities

Markets

Movers

PZZA

Papa John's Takeover Rumors Swirl, But Doubts Are Creeping In

<ul>
<li>Kulldorff served as expert witness against Merck's Gardasil</li>
<li>Kennedy fired previous vaccine advisers citing drug industry conflicts</li>
<li>CDC rules say advisers can't be expert witness in vaccine cases</li>
</ul>
June 12 (Reuters) - One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness in litigation against Merck's <a href="https://workspace.refinitiv.com/web/apps/quotewebapi?RIC=MRK.N">MRK.N</a> Gardasil vaccine, court records show.
Martin Kulldorff, a biostatistician and epidemiologist who publicly criticized COVID-era lockdowns, is one of eight new members <a href="reuters://REALTIME/verb=NewsStory/ric=nS0N3RM047">named by Kennedy on Wednesday</a> to the Advisory Committee on Immunization Practices, a highly influential panel that recommends which shots should be administered to the American public.
Kennedy fired the entire previous 17-member committee of expert vaccine advisers this week, claiming they were "plagued with persistent <a href="reuters://REALTIME/verb=NewsStory/ric=nL6N3SE0S2">conflicts of interest</a>" from financial ties to drugmakers.
Kulldorff recently served as an expert witness for plaintiffs who accused Merck of concealing the risks of Gardasil, which is intended to prevent cancers caused by human papillomavirus (HPV). In March, a federal judge in North Carolina ruled in favor of Merck in one of those cases that included about 200 lawsuits.
At a deposition in October, Kulldorff testified that the plaintiffs paid him $400 an hour and he had already billed for about $33,000 in legal work on the case through late September. He said he also received a $4,000 retainer in the North Carolina case, according to court documents.
Kulldorff is also listed as an expert witness in a similar case pending against Merck in <a href="reuters://REALTIME/verb=NewsStory/ric=nL2N3P90RI">Los Angeles</a> state court, records show.
Under ACIP's rules, committee members cannot serve as a "paid litigation consultant or expert witness in litigation involving a vaccine manufacturer" during their tenure on the panel.
Prior work as an expert witness against drugmakers may require a waiver from the U.S. Centers for Disease Control and Prevention and recusal from votes involving Merck and HPV vaccines. The agency has said in its rules it "will generally consider issuance of waivers in specific situations."
Kulldorff did not immediately respond to a request for comment. Merck declined to comment.
A spokesman for Kennedy's Health and Human Services Department said on Wednesday that "all newly appointed ACIP members were thoroughly vetted." HHS did not immediately respond to a request for comment on Kulldorff.
&nbsp;

Biotech

'A New U.S. Vaccine Adviser Named By Health Secretary Kennedy Was Expert Witness In Litigation Against Merck Vaccine' - Reuters Exclusive

<a href="https://docs.publicnow.com/viewDoc?hash_primary=E1CE3DFED04FF79443CAC8D649FD1A421CF32415" title="https://docs.publicnow.com/viewDoc?hash_primary=E1CE3DFED04FF79443CAC8D649FD1A421CF32415">https://docs.publicnow.com/viewDoc?hash_primary=E1CE3DFED04FF79443CAC8D649FD1A421CF32415</a>

TNXP

Tonix Pharmaceuticals Releases June 2025 Virtual Investor Presenation, Shares Key Updates On Pipeline And Strategic Initiatives

Guggenheim analyst John Difucci reiterates Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) with a Buy and maintains $220 price target.

Price Target

Reiteration

Analyst Ratings

ORCL

Guggenheim Reiterates Buy on Oracle, Maintains $220 Price Target

Kevin O'Leary isn't just handing out financial advice on TV—he's passing down the same wisdom he got from his mom when he was seven years old. And no, it wasn't something from a fancy finance textbook.
<a href="https://www.facebook.com/reel/1999276957207357">In a Facebook post</a>, O'Leary shared, "My mom taught me the greatest financial lesson of my life when I was seven: ‘Never spend the principal, only the interest.' Decades later, it's the backbone of my entire investment strategy."
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
</ul>
That one rule stuck. According to O'Leary, it's shaped the way he manages everything he owns. "Everything I own has to generate yield—it's about discipline, sustainability, and making your money work for you. Trust me, it works," he wrote.
He didn't stop at the post. In a video attached to it, O'Leary <a href="https://www.benzinga.com/news/25/03/44081583/my-mom-was-not-a-stock-analyst-just-a-working-woman-when-she-passed-she-was-rich-kevin-oleary-reveals-her-lifelong-process-you-can-copy">spoke about his mother</a>, Georgette, who was a disciplined saver. She'd regularly take Kevin and his younger brother to the bank—where she'd invest in bonds—and give them a crash course in cash flow.
"She'd say to us, ‘Boys, never spend the principal, only the interest,'" he recalled.
Now well into his career as an investor and television personality, O'Leary still sticks to that same philosophy. "I view my portfolio, and my trust and my positions as a chicken on a spit dripping cash," he said in the video. "Everything has to generate yield … I take that, I disperse it. The family lives off that, the charities I've committed to."
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
The logic behind it is simple but powerful: don't touch the original money you've invested—only live off the returns. That way, your wealth continues to grow.
For example, if you've got $100,000 generating 5% a year, you're making $5,000 annually. Reinvest that, and your money compounds. In about 15 years, you've doubled your wealth. But spend the $5,000 each year instead, and <a href="https://www.benzinga.com/personal-finance/management/25/06/45861901/the-fastest-way-to-make-a-million-dollars-is-to-make-the-first-10000-says-kevin-oleary-and-it-starts-with-solving-just-1-problem">you're stuck at that same $100,000</a>. Start dipping into the principal itself? You're draining the pot—fast.
In O'Leary's words, everything has to work for him. And the secret to that system? Yield. It's a <a href="https://www.benzinga.com/markets/tech/25/06/45851993/mr-wonderful-kevin-oleary-says-he-was-once-told-by-a-ceo-to-shut-up-and-that-leveled-up-his-negotiation-skills-fellow-shark-mark-cuban-also-fle">mindset of preservation</a>, not depletion.
So while some people grow up with piggy banks and spending sprees, O'Leary grew up hearing one clear mantra: protect the principal. Let the interest do the heavy lifting. And decades later, that one line from his mother still runs the show.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
Image: Shutterstock

Personal Finance

'Boys, Never Spend The Principal, Only The Interest' — Kevin O' Leary's Mom Taught Him The Best Money Lesson Of His Life At 7

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) has outperformed the market over the past 5 years by 8.41% on an annualized basis producing an average annual return of 22.42%. Currently, AECOM has a market capitalization of $14.84 billion. 
Buying $100 In ACM: If an investor had bought $100 of ACM stock 5 years ago, it would be worth $285.84 today based on a price of $112.21 for ACM at the time of writing.
<h3>AECOM's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749741314_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning AECOM Stock In The Last 5 Years

BMO Capital analyst Stephen MacLeod maintains North West Co (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NWC#TSX">NWC</a>) with a Outperform and lowers the price target from C$60 to C$59.

TSX:NWC

BMO Capital Maintains Outperform on North West Co, Lowers Price Target to C$59

Citigroup analyst Anthony Pettinari maintains Core &amp; Main (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNM#NYSE">CNM</a>) with a Neutral and raises the price target from $56 to $62.

Citigroup Maintains Neutral on Core & Main, Raises Price Target to $62

BMO Capital analyst Kelly Bania maintains United Natural Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) with a Market Perform and lowers the price target from $32 to $25.

UNFI

BMO Capital Maintains Market Perform on United Natural Foods, Lowers Price Target to $25

BlackRock Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) on Thursday outlined a plan to raise $400 billion in alternative assets by 2030 and increase total revenue from $20 billion to over $35 billion in the same period.
According to BlackRock&#8217;s <a href="https://s24.q4cdn.com/856567660/files/doc_presentations/2025/BLK-Investor-Day-2025-WEB.pdf" target="_blank" rel="noreferrer noopener">Investor Day 2025 presentation</a>, the asset manager detailed a long-term strategy focused on expanding its private market exposure and scaling its technology platforms. 
Private markets currently contribute 15% of total revenue, but BlackRock aims to grow that share to more than 30% by the end of the decade.
Also Read: <a href="https://www.benzinga.com/news/topics/25/06/45851858/psiquantum-eyes-750m-raise-as-blackrock-doubles-down-on-light-based-supercomputers-amid-nvidias-quantum-reversal" target="_blank" rel="noreferrer noopener">PsiQuantum Eyes $750M Raise As BlackRock Doubles Down On Light-Based Supercomputers Amid Nvidia&#8217;s Quantum Reversal</a>
The company plans to double adjusted operating income from $8 billion to $15 billion and expand market capitalization from $140 billion to $280 billion. It reported returning $9 billion to investors through private market realizations following its Global Infrastructure Partners acquisition.
At the end of the first quarter, BlackRock&#8217;s total Assets Under Management was $11.6 trillion, compared to $10.5 trillion in the prior year quarter.
The strategy includes integrating Preqin&#8217;s data into the Aladdin platform to support benchmarking and analytics for private markets. BlackRock expects to begin onboarding <a href="https://www.benzinga.com/24/11/42227693/blackrock-set-to-acquire-private-credit-manager-hps-for-12b-report" target="_blank" rel="noreferrer noopener">HPS Investment Partners</a> in the third quarter, enhancing capabilities in private credit and insurance.
Aladdin generated $1.6 billion in revenue in 2024, with a $20 billion addressable market opportunity. The firm also manages $50 billion in crypto-related assets, including Circle&#8217;s USDC reserves and the IBIT bitcoin ETF.
Leadership roles were also highlighted, with CFO Martin Small and COO Rob Goldstein prominently featured in the strategy rollout, though CEO Larry Fink&#8216;s succession plan was not directly addressed.
Price Action: BLK shares are trading lower 0.26% to $990.70 at last check Thursday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45891293/amex-still-king-of-premium-credit-cards-but-chase-capital-one-are-closing-in-" target="_blank" rel="noreferrer noopener">Amex Still King Of Premium Credit Cards — But Chase, Capital One Are Closing In Fast: Analyst</a></li>
</ul>
Photo via Shutterstock

Large Cap

BlackRock Targets $280 Billion Market Cap, $35 Billion Revenue By 2030

Guidance

Cardinal Health Expecting At Least $10B In Total Adjusted Free Cash Flow Over Next 3-Years; Raising Baseline Share Repurchase Plans To At Least $750M Per Year

BMO Capital analyst Keith Bachman maintains SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Outperform and raises the price target from $26 to $27.

SAIL

BMO Capital Maintains Outperform on SailPoint, Raises Price Target to $27

BioNTech SE&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) on Thursday agreed to acquire CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) in an <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">all-stock transaction</a>.
According to the agreement, shareholders can exchange CureVac shares for around $5.46 in BioNTech ADSs. This equates, roughly, to an equity value of <a href="https://www.benzinga.com/pressreleases/25/06/g45900311/biontech-announces-strategic-transaction-to-acquire-curevac-in-public-exchange-offer" target="_blank" rel="noreferrer noopener">$1.25 billion</a>.
The consideration is subject to a collar mechanism. If the 10-day volume weighted average price of the BioNTech ADSs ending on the fifth business day before the offer&#8217;s closing exceeds $126.55, the exchange ratio would be 0.04318. If the VWAP is lower than $84.37, the exchange ratio would be 0.06476.
At closing, CureVac shareholders expect to own between 4% and 6% of BioNTech.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45853393/robert-kennedy-jr-axes-entire-cdc-vaccine-panel-to-restore-public-trust-pfizer-moderna-other-biotech-stocks-drop-in-after-hours-trading" rel="noreferrer noopener">Robert Kennedy Jr Axes Entire CDC Vaccine Panel To &#8216;Restore Public Trust&#8217; — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading</a>
With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy.
The strategic transaction will complement BioNTech&#8217;s capabilities and proprietary technologies in mRNA design, delivery formulations, and manufacturing.
For BioNTech, this transaction marks the next milestone in the execution of its oncology strategy which focuses on two pan-tumor programs, mRNA-based cancer immunotherapy candidates, and BNT327, a PD-L1xVEGF-A bispecific antibody candidate.
Following the transaction&#8217;s closing, CureVac&#8217;s operating subsidiary will become a wholly owned subsidiary of BioNTech. As part of this plan, BioNTech will integrate CureVac&#8217;s research and manufacturing site in Tübingen.
The transaction was unanimously approved by BioNTech&#8217;s and CureVac&#8217;s management and supervisory boards. The transaction is expected to close in 2025.
As of March 31, BioNTech had 15.9 billion euros in cash, cash equivalents, <a href="https://www.benzinga.com/25/05/45205736/biontech-appoints-novartis-executive-as-finance-chief-reaffirms-2025-guidance-focuses-on-oncology-expansion" target="_blank" rel="noreferrer noopener">and security investments</a>.
Earlier in June, BioNTech and&nbsp;Bristol Myers Squibb&nbsp;&amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) entered into a co-development and <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45723383/bristol-myers-inks-11-billion-licensing-pact-with-biontech-for-bispecific-cancer-drug" rel="noreferrer noopener">co-commercialization agreement</a>.
The pact focuses on BioNTech&#8217;s investigational bispecific antibody BNT327 across numerous solid tumor types.
Bristol Myers Squibb will pay BioNTech $1.5 billion upfront and $2 billion in non-contingent anniversary payments through 2028.
In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones.
In March, CureVac said the European Patent Office (EPO) confirmed the validity of CureVac&#8217;s European patent EP 3 708 668 B1 subject to amendments to specify <a target="_blank" href="https://www.benzinga.com/25/03/44535393/european-patent-office-rules-vaccine-developer-curevacs-amended-patent-valid-stock-jumps" rel="noreferrer noopener">the scope of protection</a>.
The opposition division largely dismissed BioNTech&#8217;s original opposition filed in April 2023, challenging the patent&#8217;s validity and maintaining it in amended form.
Price Action: BNTX stock is up 1.22% at $106.75, and CVAC stock is up 33.2% at $5.42 during the premarket session at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45887132/novavaxs-experimental-covid-19-influenza-combo-shot-shows-immune-response-among-older-adults-in-phase-3-trial" target="_blank" rel="noreferrer noopener">Novavax&#8217;s Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial</a></li>
</ul>
Image: Shutterstock

Health Care

BNTX

CVAC

NVAX

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

Cardinal Health Raises FY25 Non-GAAP Diluted EPS Guidance To $8.15 - $8.20

DA Davidson analyst Rudy Kessinger maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Buy and raises the price target from $435 to $465.

CYBR

DA Davidson Maintains Buy on CyberArk Software, Raises Price Target to $465

Preliminary fiscal year 2026 guidance The company is providing preliminary guidance for fiscal year 2026:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Non-GAAP diluted EPS</td>
<td colspan="1" rowspan="1">
$9.10 to $9.30
(+13% growth at mid-points)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted free cash flow</td>
<td colspan="1" rowspan="1">$2.75B to $3.25B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures</td>
<td colspan="1" rowspan="1">~$600M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest and other</td>
<td colspan="1" rowspan="1">~$275M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP effective tax rate</td>
<td colspan="1" rowspan="1">22% to 24%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pharmaceutical and Specialty Solutions:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue</td>
<td colspan="1" rowspan="1">11% to 13% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Reported)</td>
<td colspan="1" rowspan="1">10% to 12% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Segment profit (Normalized)4</td>
<td colspan="1" rowspan="1">5% to 7% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Global Medical Products and Distribution:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue</td>
<td colspan="1" rowspan="1">3% to 5% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit</td>
<td colspan="1" rowspan="1">&nbsp;$140M+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other5:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue (Reported)</td>
<td colspan="1" rowspan="1">26% to 28% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Reported)</td>
<td colspan="1" rowspan="1">25% to 27% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue (Normalized)4</td>
<td colspan="1" rowspan="1">10% to 12% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Normalized)4</td>
<td colspan="1" rowspan="1">~10% growth</td>
</tr>
</tbody>
</table>
</figure>
Long-term targets The company is providing updated long-term targets (fiscal years 2026 to 2028 CAGRs3):
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Non-GAAP diluted EPS</td>
<td colspan="1" rowspan="1">12% to 14% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pharmaceutical and Specialty Solutions:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue</td>
<td colspan="1" rowspan="1">8% to 10% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Reported)</td>
<td colspan="1" rowspan="1">7% to 9% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Normalized)4</td>
<td colspan="1" rowspan="1">5% to 7% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Global Medical Products and Distribution:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue</td>
<td colspan="1" rowspan="1">2% to 4% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit</td>
<td colspan="1" rowspan="1">$50M+ of profit growth per year after FY26</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other5:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue (Reported)</td>
<td colspan="1" rowspan="1">16% to 18% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Reported)</td>
<td colspan="1" rowspan="1">15% to 17% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue (Normalized)4</td>
<td colspan="1" rowspan="1">10% to 12% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Normalized)4</td>
<td colspan="1" rowspan="1">~10% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp; Adjusted Free Cash Flow (FY26 to FY28 total)</td>
<td colspan="1" rowspan="1">At least $10B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp; Share Repurchases (FY26 to FY28 total)</td>
<td colspan="1" rowspan="1">At least $2.25B</td>
</tr>
</tbody>
</table>
</figure>

Cardinal Health Provides Preliminary FY26 Guidance With Non-GAAP EPS Of $9.10-$9.30, Adj. FCF Of $2.75B-$3.25B, Capital Expenditures ~$600M, Sees Segment Revenue Growth Across Key Divisions; Updates Long-Term Targets Through 2028 Including 12% - 14% EPS CAGR And Revenue Growth Across Key Divisions

WIIM

LOVE

Lovesac shares are trading lower despite reporting better-than-expected Q1 results. The company announced plans to exit its Best Buy partnership, reduce its workforce by 8%, and incur $1.7M–$2.1M in related costs.

Press Releases

Federal Home Loan Bank of Dallas, Cadence Bank and Citizens National Bank Award $9K Grant to Hattiesburg, Mississippi, Housing Nonprofit

Cadence Bank Receives Regulatory Approvals for its Merger with FCB Financial Corp.

Cadence Bank Announces First Quarter 2025 Earnings Webcast Schedule

Dividends

Cadence Bank Declares Special Preferred Dividend to be Paid if Favorable Vote Received and Announces Adjournment of its Special Meeting to Solicit Additional Votes

Comments

Cadence Bank

매도 수량

Cadence Bank (NYSE:CADE) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌